Merimepodib, pegylated interferon, and r
✍
Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr
📂
Article
📅
2009
🏛
John Wiley and Sons
🌐
English
⚖ 240 KB
👁 1 views
on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a